Related Experiment Video
Updated: Jul 23, 2025
06:16
Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models
Published on: March 16, 2022
3.0K
AAV Serotypes and Their Suitability for Retinal Gene Therapy
Lynn J A Ebner1, Christian Grimm2
1Lab for Retinal Cell Biology, Department of Ophthalmology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland. Lynn.Jenny.Alix.Ebner@uzh.ch.
Advances in Experimental Medicine and Biology
|July 13, 2023
Summary
Retinal gene therapy, particularly adeno-associated virus (AAV)-based treatments, has advanced significantly, offering new hope for inherited retinal diseases (IRDs). Ongoing research focuses on novel AAV vectors and delivery methods to improve efficacy for various eye conditions.
Area of Science:
- Ophthalmology
- Genetics
- Molecular Medicine
Background:
- Significant advancements in retinal gene therapy over the past 25 years.
- FDA approval of adeno-associated virus (AAV)-based gene therapy for Leber congenital amaurosis type 2 (LCA2) in 2017 marked a major breakthrough.
- Numerous therapies for inherited retinal diseases (IRDs) are progressing through clinical trials.
Purpose of the Study:
- To review the progress and current state of retinal gene therapy.
- To highlight the role of advanced vector design and gene transfer methods.
- To discuss factors influencing the efficiency of gene therapy for eye diseases.
Main Methods:
- Review of existing literature on retinal gene therapy and adeno-associated virus (AAV) vectors.
- Analysis of clinical trial progress for various inherited retinal diseases (IRDs).
- Discussion of emerging technologies in vector design, gene transfer, and delivery methods.
Main Results:
- Adeno-associated virus (AAV)-based gene therapy has shown success, with FDA approval for LCA2.
- Multiple IRD therapies are in early-phase clinical trials, targeting conditions like retinitis pigmentosa and Stargardt disease.
- Novel AAV serotypes, improved gene transfer, and gene editing techniques are being developed.
Conclusions:
- Advanced vector and capsid design, alongside refined gene transfer and editing, promise improved therapies for eye diseases.
- Optimizing transgene expression through novel AAV serotypes is a global research focus.
- Injection method and tissue-specific promoters are critical for efficient cell targeting and therapeutic outcomes.
